Synairgen Share Price (SNG)

Find Your Broker

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Synairgen Plc	LSE:SNG	London	Ordinary Share	GB00B0381Z20	ORD 1P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	+0.00p	+0.00%	13.75p	0	08:00:00

Bid Price		Offer Price	High Price	Low Price	Open Price
13.00p		14.50p	13.75p	13.75p	13.75p

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	5.03	1.63	1.93	7.1	15.0

Related Shares
AstraZeneca (AZN), GlaxoSmithKline (GSK), Venn Life (VENN), Port Erin (PEBI)

Synairgen (SNG) Latest News

Synairgen News

Date	Time	Source	Headline
22/10/2018	10:53	ALNC	Synairgen Begins Dosing For Next Stage Of SNG001 Clinical Trial
22/10/2018	09:05	UKREG	Synairgen plc Holding(s) in Company
22/10/2018	06:38	ALNCF	Alliance News Flash Headline
22/10/2018	06:00	UKREG	Synairgen plc Part 2 start of Phase II COPD trial
16/10/2018	14:01	UKREG	Synairgen plc Holding(s) in Company
15/10/2018	07:49	UKREG	Synairgen plc Holding(s) in Company
12/10/2018	10:05	UKREG	Synairgen plc Result of General Meeting
12/10/2018	09:29	UKREG	Synairgen plc Result of General Meeting
25/9/2018	16:56	UKREG	Synairgen plc Result of Fundraise
25/9/2018	12:48	ALNC	Synairgen Fundraises To Progress Clinical Tests As Interim Loss Widens..

More Synairgen News

Synairgen Takeover Rumours

Synairgen (SNG) Share Charts

1 Year Synairgen Chart

1 Month Synairgen Chart

Intraday Synairgen Chart

Synairgen (SNG) Discussions and Chat

Synairgen Forums and Chat

Date	Time	Title	Posts
06/12/2018	08:29	Synairgen - a cure for Asthma?	935
19/10/2010	07:22	Synairgen - Blockbusting potential	50
17/3/2010	18:34	Canadian Superior Energy: No.American Gas&Oil	8

Add a New Thread

Synairgen (SNG) Most Recent Trades

No Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type

View all Synairgen trades in real-time

Synairgen (SNG) Top Chat Posts

Date	Subject
14/12/2018 08:20	Synairgen Daily Update: Synairgen Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SNG. The last closing price for Synairgen was 13.75p. Synairgen Plc has a 4 week average price of 13.50p and a 12 week average price of 13.50p. The 1 year high share price is 26.50p while the 1 year low share price is currently 10.88p. There are currently 109,433,442 shares in issue and the average daily traded volume is 14,256 shares. The market capitalisation of Synairgen Plc is £15,047,098.28. Read Full Thread Reply
15/10/2018 07:55	richthenewbie: Leonard Licht still accumulating here (may have been during placing). His stake up to nearly 10% now: https://uk.advfn.com/stock-market/london/synairgen-SNG/share-news/Synairgen-plc-Holdings-in-Company/78458565 Read Full Thread Follow Reply
04/8/2018 08:20	pdt: gab147 - hTTps://www.asx.com.au/asx/share-price-research/company/PXS scroll down the page to announcements and it is contained in the "Trading Halt" release. Read Full Thread Follow Reply
27/7/2018 07:18	gab147: I agree with you Nobby - the share price should be double at least if it truly represents the potential future income from these drugs. Read Full Thread Follow Reply
22/6/2018 06:46	ohisay: Much as expected and I'd be surprised if the biomarker results weren't just as good as in previous years . This was from last years results (primarily commenting on the AZ Inexas trial ). https://uk.advfn.com/stock-market/london/synairgen-SNG/share-news/Synairgen-plc-Interim-results-for-six-months-ended/75732062 We are however very encouraged to observe that the lungs' antiviral defences had been switched on - as demonstrated by significant changes in an accepted biomarker of the interferon pathway. Indeed this is the third trial where this activation has been shown. Finncap had an extra 10p to add to their initial 35p target for a confirmed safety/biomarker COPD result so still all to play for here. Read Full Thread Follow Reply
30/5/2018 10:05	ohisay: Indeed .COPD safety study due first I think. Worth recalling the House broker view ... Broker FinnCap reckons the stock is worth 35p based on a discounted cash flow (DCF) valuation that that puts 17p and 18p a share price tags on, respectively, SNG001 and LOXL2. This DCF valuation will rise to £41mln, or 45p a share following the successful completion of a pilot safety study of SNG001 Read Full Thread Follow Reply
14/2/2018 11:23	rosejs2: Nobby... You are not talking to yourself.. I agree with all of your points.. SNG is a unique share... the 17% of Pharmaxis LOXL2 offers huge opportunity .. with an expected upfront payment to Pharmaxis of up to $50m (if the Phase 1 trials prove successful) and further signifcant stage payments on its journey to commercialisation. The Income coffers of SNG COULD soon be flush with substantial additional funds.. With the commencement of Phase 2 Trials on SNGs own Interferon B now underway... with initial results in Q2 2018...There cannot be a share as unique as SNG to hold.. No debt, enough cash rerserves topped up by the recent £5m payment from Pharmaxis achieving full control of the LOXL2 programme .. It is a share to watch, hold and wait for information that can and might lead to many multiples of its current share price.. IMHO. Read Full Thread Follow Reply
29/12/2017 17:10	rosejs2: SNG appears to be an invisible gem to the majority of Investors.. We have a unique British Company based in Southampton General Hospital using its differentiating human biology BioBank platform and world-renowned international academic Key Opinion Leader network to discover and develop novel therapies for respiratory disease.Prof Stephen Holgate, Medical Research Council Clinical Professor of Immunopharmacology at the University of Southampton is a Non Exec Director of SN SNG will very soon have £5m from Pharmaxis, plus my guess is approx £2.0 million in its cash reserves.. and importantly NO DEBT... Approx 64% of the shares are held by 5 shareholders with Woodford Investment Managers holding over 23% of the SNG share capital..and approx 91 Million shares in existance.. With a dynamic management led by CEO Richard Marsden, who I calculate pulled off a unique and lucrative deal of SNG investing my guess is £3m in LOXL2 and 2 years later has converted this investment into a £5m Paycheck for shareholders and critcally important a 17% stake in the COMPLETE Pharmaxis LOXL Programme... Phase 1 Trials by Pharmaxis in the LOXL Programme are commencing with the following comment by its CEO “Ongoing discussions with multinational Pharma companies suggest that there is a significant opportunity for an oral once a day LOXL2 inhibitor in a number of fibrotic diseases with a high unmet need. With COPD news by SNG expected sometime after Q1 2018 and regular updates by Pharmaxis on its LOXL Programme during Q1 and Q2 2018... The potential risk reward for Synairgen shareholders does offer a very signifcant reward opportunity.. for those willing to complete the journey to see both these key Programmes end points.. A very successful and prosperous New Year to current and future SNG Investors. Read Full Thread Follow Reply
19/12/2017 19:18	rosejs2: ohisay ... I do agree with your sentiments.. Here we have a company with NO debt, £5m to come from Pharmaxis, 17% of future revenues from LOXL2 Developments (these could be huge if the Phase 1 trials meet expectations and the right partners found)... Approx £2m in current cash... Alongside progression of SNG001 into COPD, What is there not to like.. If you look at the Major shareholders 5 of which including Woodford Investment Management own approx 64% of the issued equity...only 91.36 million shares... Both areas of development LOXL2 and COPD are if successfull worth Billions to major Pharma Partners... whilst the 'IF' is speculative.. the quality of both Management and Scientific Expertise in both Pharmaxis and SNG is second to none.. Why is the share price falling ? my view for what it is worth is that SNG shares are quite illiquid small sales or purchases can move the price one way or the other .. and currently some small sells are driving the price down.. It may on the other hand be a tree shaking exercise by the market makers who require stock to meet their obligations.. and hitting individual stop losses may be the only way to obtain stock... but that is just my speculation.. 2018 will be a very exciting year for SNG for both LOXL2 and progress on COPD ... If SNG management can supply regular updates on progress, the market should become more aware of the real potential of SNG and its revenue streams. The market should then respond positively in raising SNG shares substantially above its current lowly Price.. Read Full Thread Follow Reply
17/12/2017 13:30	rosejs2: Has it occured to others why Pharmaxis did not bid for SNG as a means of achieving 100% ownership of the LOXL2 Programme ? or was there an attempt to do so before signing the latest agreement with SNG to share revenues... Might the large shareholders have been (quite rightly ) demanding a price substantially in excess of the current share price ? Might Pharmaxis be a future bidder of SNG if all goes well with its Phase 1 / Partnership agreements... And be able to add SNG's COPD potential blockbuster to its portfolio ? Read Full Thread Follow Reply
18/7/2016 19:57	wookie77: Thanks Ohisay........If SNG share price can get above the 40p neck line then we really are off to the races IMO. Read Full Thread Follow Reply

Synairgen share price data is direct from the London Stock Exchange

Your Recent History

LSE

SNG

Synairgen

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P: V: D:20181215 07:31:13